Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/30/16
End: 11/30/16
Due: 11/30/17
Phase: N/A
Priority: Normal
Start: 11/01/11
End: 02/17/17
Due: 02/17/18
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 10/31/22
Due: 10/31/23
Phase: N/A
Priority: Normal
Start: 02/29/12
End: 03/31/16
Due: 03/31/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | NCT02757248 | Anne Beaven, MD | user2@example.com | None | 2016-11-30 | 2016-11-30 | 2017-11-30 | - | - | 2025-07-14 |
| IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma | NCT01491841 | Anne Beaven, MD | user2@example.com | None | 2011-11-01 | 2017-02-17 | 2018-02-17 | - | - | 2025-07-14 |
| Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | NCT02343679 | Anne Beaven, MD | user2@example.com | None | 2015-05-31 | 2022-10-31 | 2023-10-31 | - | - | 2025-07-14 |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT00978432 | Anne Beaven, MD | user2@example.com | None | 2012-02-29 | 2016-03-31 | 2017-03-31 | - | - | 2025-07-14 |